

Article

Glutathione-capped Ag₂S nanoclusters inhibit coronavirus proliferation through blockage of viral RNA synthesis and budding

Ting Du, Jianguo Liang, Nan Dong, Jian Lu, Yiyi Fu, Liurong Fang, Shaobo Xiao, and Heyou Han

ACS Appl. Mater. Interfaces, **Just Accepted Manuscript** • DOI: 10.1021/acsami.7b13811 • Publication Date (Web): 16 Jan 2018Downloaded from <http://pubs.acs.org> on January 16, 2018**Just Accepted**

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3
4 **Glutathione-capped Ag₂S nanoclusters inhibit coronavirus proliferation through**
5
6 **blockage of viral RNA synthesis and budding**
7

8 Ting Du,¹ Jiangong Liang,¹ Nan Dong,² Jian Lu,¹ Yiying Fu,¹ Liurong Fang,² Shaobo
9
10 Xiao,^{2,*} and Heyou Han^{1,*}
11
12

13
14 ¹State Key Laboratory of Agricultural Microbiology, College of Food Science and
15
16 Technology, College of Science, Huazhong Agricultural University, Wuhan 430070,
17
18 PR China.
19

20
21 ²State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine,
22
23 Huazhong Agricultural University, Wuhan 430070, PR China.
24
25

26
27
28
29 ABSTRACT: Development of novel antiviral reagents is of great importance for the
30
31 control of virus spread. Here, Ag₂S nanoclusters (NCs) were proved for the first time
32
33 to possess highly efficient antiviral activity by using porcine epidemic diarrhea virus
34
35 (PEDV) as a model of *coronavirus*. Analyses of virus titers showed that Ag₂S NCs
36
37 significantly suppressed the infection of PEDV by about three orders of magnitude at
38
39 the noncytotoxic concentration at 12 hour post infection, which was further confirmed
40
41 by the expression of viral proteins. Mechanism investigations indicated that Ag₂S NCs
42
43 treatment inhibits the synthesis of viral negative-strand RNA and viral budding. Ag₂S
44
45 NCs treatment was also found to positively regulate the generation of IFN-stimulating
46
47 genes (ISGs) and the expression of pro-inflammation cytokines, which might prevent
48
49 PEDV infection. This study suggest the novel underlying of Ag₂S NCs as a promising
50
51 therapeutic drug for *coronavirus*.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

KEYWORDS: Ag₂S nanoclusters, antiviral, replication, IFN-stimulating genes, pro-inflammation cytokines

1. INTRODUCTION

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

Nanoparticles have shown great potential advantages in antiviral activity. Up to now, several kinds of nanoparticles have been reported to exhibit antiviral activity to a certain extent, such as silver nanoparticles,¹⁻³ functional gold nanoparticles,^{4,5} carbon-based nanomaterials,⁶⁻¹⁰ polyoxometalate,^{11,12} nanoclay¹³ and silicon nanoparticles.¹⁴ Generally, aiming the early stages of viral absorption and entry was the most universal tactics in the course of development of antiviral therapies.¹⁵⁻¹⁷ Like other biological interactions, the properties of the nanostructures allow them to adapt well to competing with these recognition sites to inhibit viral entry into cells.^{18,19} However, there were several common drawbacks for the previously reported antiviral materials. For instance, the widely used strategy was based on blocking viral attachment or viral entry into cells, and the nanoparticles have no suppressive effect of on the progeny of the virus in the late viral replication.^{20,21} Therefore, more efforts should be made to develop safe, high-performance antiviral drugs targeting different stages of virus infectious life cycle.


45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Coronavirus is a life threatening virus that could lead to serious respiratory tract infectious diseases in humans. Porcine epidemic diarrhea virus (PEDV), a positive-strand RNA virus, membering of the family *Coronaviridae* and genus *Alphacoronavirus*, is a vital animal virus model for the study of coronavirus. As a serious, highly epidemical and ruinous intestinal disease, PEDV has brought

1
2
3 tremendous financial loss in the global swine industry, especially in China, Korea,
4 Japan and Thailand, since it was first found in piglets and fattening swine in
5
6 Europe.^{22,23} Unfortunately, the control of PEDV was primarily dependent on
7
8 vaccination in advance, suggesting the necessity of developing novel antiviral drugs.
9
10

11
12
13 Ag₂S nanocrystals, also called quantum dots (QDs), are a class of ideal
14
15 narrow-band-gap NIR fluorescent materials,²⁴ and have been used in optical and
16
17 electronic devices, biolabeling and bioimaging, due to their advantages of low or no
18
19 toxicity to living tissues, good chemical stability and outstanding optical limiting
20
21 properties.^{25,26} Wan's group has reported that NO can be released by glutathione (GSH)
22
23 stabilized Ag₂S QDs conjugated with RSNOs under certain light irradiation with the
24
25 function of NIR fluorescence imaging.²⁷ Achilefu's group has successfully conjugated
26
27 a tumor-avid peptide to Ag₂S QDs that can be selectively delivered to tumor cells and
28
29 tissue.²⁸ Chen's group has shown that Ag₂S nanocrystals can be used as photothermal
30
31 therapy agents *in vitro* and *in vivo*.²⁹ Meng's group has proposed a DNA logic gate
32
33 platform to enable the realization of femtomolar level miRNA analysis through NIR
34
35 Ag₂S nanocrystals for their autofluorescence properties.³⁰ To our knowledge, there is
36
37 still no report available about the function of Ag₂S NCs as an antiviral agent.
38
39
40
41
42
43
44

45 Here, we report the use of Ag₂S NCs for viral inhibition (**Scheme 1**). Assays *in*
46
47 *vitro* showed that cells treated with Ag₂S NCs restrained the propagation of PEDV
48
49 possibly through inhibiting the synthesis of viral negative-strand RNA and viral
50
51 budding. In addition, the antiviral activity of the Ag₂S NCs also might be attributed to
52
53 the activation of ISG proteins and pro-inflammatory cytokines.
54
55
56
57
58
59
60



Scheme 1. Possible mechanisms of the antiviral activity of Ag₂S NCs. The replication cycle of viruses consists of the four consecutive steps of attachment, penetration, replication and budding. The study of underlying molecular mechanisms indicated that Ag₂S NCs treatment inhibits the synthesis of viral negative-strand RNA and viral budding. Meanwhile, the production of ISGs and the up-regulation of pro-inflammatory cytokines might have a crucial role in the inhibitory effect of Ag₂S NCs.

2. EXPERIMENTAL SECTION

2.1. Synthesis of Ag₂S NCs. In this work, the synthesis of glutathione (GSH) capped Ag₂S NCs was based on the previous literature.³¹ Selecting the suitable capping reagent is the key to the preparation of tunable Ag₂S NCs. GSH is a small molecule peptide that consists of three amino acids and can serve as a vital scaffold to prevent the growth of large nanoparticles. In addition, GSH contains multiple functional groups, indicating that the resulting GSH-capped Ag₂S NCs will have good

1
2
3 water solubility. For synthesis of Ag₂S NCs, 0.160 g sulfur was added to 10.0 mL
4
5 hydrazine hydrate (N₂H₄·H₂O) and stirred at ambient temperature to thoroughly
6
7 dissolve. After sedimentating for 48 h at 4 °C, the resulting aqueous S²⁻ source was
8
9 diluted 20 times before further use as the S²⁻ source, and then supramolecular
10
11 hydrogel were formed by mixing GSH and Ag⁺ (AgNO₃ as the Ag⁺ source) in a fixed
12
13 molar ratio in N₂ atmosphere. Next, 4.0 mL S²⁻ source solution was injected and
14
15 stirred constantly for 30 min. The obtained Ag₂S NCs were purified by adding
16
17 isopropanol, followed by centrifuging the mixture. Finally, the precipitate was
18
19 redispersed in ultrapure water and kept at 4 °C for future use. GSH-capped Ag₂S NCs
20
21 with a different FL wavelength were synthesized through changing the amount GSH
22
23 and the proportion of Ag⁺ to S-N₂H₄·H₂O.
24
25
26
27
28
29

30 **2.2. Cell viability.** Vero cells were cultured in the 96-well plates until
31
32 approximately 80-90% confluence, the cells were exposed with different
33
34 concentrations (23, 46, 92 μg/mL) of Ag₂S NCs and GSH (10 mM). Cells treated with
35
36 the DMEM (2% FBS) were used as control. After culturing the cells for 24 and 48 h,
37
38 the supernatant was superseded by 100 μL DMEM (2% FBS) and 20 μL MTT reagent
39
40 (5 mg/mL). Through further 4 h of incubation, 150 μL dimethyl sulfoxide (DMSO)
41
42 solution was supplemented after the medium was discarded. OD value at 570 nm was
43
44 measured.
45
46
47
48
49

50 **2.3. One-step growth curves.** 80-90% confluence Vero cells were incubated with
51
52 control DMEM (containing 10 μg/mL trypsin) or Ag₂S NCs at 37 °C for 2 h.
53
54 Subsequently, the Vero cells were treated with PEDV at 37 °C at a multiplicity of
55
56
57
58
59
60

1
2
3 infection (MOI) of 0.01. After 1 h infection, the inoculums were discarded, then the
4
5 cell monolayers were cultured separately in control DMEM (containing 10 $\mu\text{g}/\text{mL}$
6
7 trypsin) or Ag_2S NCs at 37 $^\circ\text{C}$ for 1, 3, 6, 9, 12, 24, 36, 48, 60 and 72 hours post
8
9 infection (hpi). After three freeze-thaw cycles, removal of cell debris by centrifuging
10
11 the cells at 4 $^\circ\text{C}$. The average titers of all samples were measured via plaque assay.^{32,33}
12
13
14

15
16 **2.4. Plaque assays.** The plaque assays of PEDV were performed according to the
17
18 previously reported with minor modifications.³⁴ In brief, Vero cells were inoculated
19
20 and incubated in DMEM (10% FBS) in a 6-well plate until 90-100% confluence,
21
22 followed by infection with 10-fold dilutions (800 $\mu\text{L}/\text{well}$) of PEDV-containing
23
24 inoculum to allow virus infection for 1 h. Then the cell monolayers were coated with
25
26 Bacto agarose and 2 \times DMEM in a fixed volume ratio of 1:1 (including 10 $\mu\text{g}/\text{mL}$
27
28 trypsin). At 2-3 days post infection, the plaques were counted. Through three
29
30 independent experiments, the standard deviations and average plaque number were
31
32 calculated. All the virus titers were displayed as plaque forming units (PFU)/mL.
33
34
35
36

37
38 **2.5. Indirect immunofluorescence.** Vero cells were cultured to approximately
39
40 70-80% confluence, then unexposed or exposed with Ag_2S NCs for 2 h, followed by
41
42 washing twice with PBS and infection with PEDV at 0.01 MOI. After 1 h of
43
44 incubation, removal of free viruses through extensive rinsing and the Vero cells were
45
46 incubated with control DMEM (containing 10 $\mu\text{g}/\text{mL}$ trypsin) or Ag_2S NCs for 12 h.
47
48 Next, the fixation of cells was performed with cold 4% paraformaldehyde for 15 min
49
50 and the permeabilization was carried out with methanol (-20 $^\circ\text{C}$) at the ambient
51
52 temperature. Next, the PEDV-infected Vero cells were blocked by 5% (w/v) BSA for
53
54
55
56
57
58
59
60

1
2
3
4 45 min, then measured with a mouse monoclonal antibody against the PEDV N
5
6 protein and FITC-conjugated goat anti-mouse IgG antibody (Invitrogen).
7
8 Subsequently, cells nucleus were counterstained with DAPI. After three washes, the
9
10 photographs were obtained by an Olympus IX73 microscope.
11
12

13 **2.6. Western blot.** Vero cells were unexposed or exposed with Ag₂S NCs for 2 h,
14
15 followed by infection with 0.05 MOI PEDV. After 1 h of infection, the cell
16
17 monolayers were incubated with control DMEM (containing 10 µg/mL trypsin) and
18
19 Ag₂S NCs for 12 h, then harvested by adding 150 µL lysis buffer. After boiling the
20
21 whole cell extracts in SDS protein sample buffer, equivalent samples were performed
22
23 with 12% SDS-polyacrylamide gel electrophoresis and then the expression of the
24
25 PEDV N protein was determined. The expression of β-actin was investigated to
26
27 represent a same amount of protein sample loading.
28
29
30
31

32 **2.7. Influence of Ag⁺ and S²⁻ on viral replication.** To measure the effect of the
33
34 release of Ag⁺ from Ag₂S NCs on viral replication, Vero cells were unexposed or
35
36 exposed with different concentrations of Ag⁺ (or S²⁻) at 37 °C. Next, Vero cells were
37
38 treated with PEDV at 0.01 MOI. After 1 h of infection, the cells were extensively
39
40 rinsed to clear the free viruses and then treated with control DMEM (containing 10
41
42 µg/mL trypsin) or different concentrations of Ag⁺ (or S²⁻) for 24 hpi. The remaining
43
44 steps are consistent with indirect immunofluorescence assays.
45
46
47
48
49

50 Furthermore, the effect of Ag⁺ (or S²⁻) on viral replication was quantitatively
51
52 verified by measuring virus titer. Briefly, after mock-treatment or treatment with
53
54 various concentrations of Ag⁺ (or S²⁻), the cells were then treated with PEDV. After 1
55
56
57
58
59
60

1
2
3 h of infection, cells were rinsed with PBS and incubation with control DMEM or Ag⁺
4
5
6 (or S²⁻) for 24 h. Finally, the cells were harvested and stored in ultra-low temperature
7
8 refrigerator. The average titers of all samples were calculated through plaque assays.
9

10
11 **2.8. Attachment assay.** The 90-100% confluent Vero cells were prechilled at 4 °C
12
13 for 30 min. PEDV samples containing different concentrations of Ag₂S NCs were
14
15 added into 6-well plates and cultured at 4 °C to permit virus attachment. After 2 h of
16
17 incubation, the attachment was stopped by two washes of the cells with ice-cold PBS.
18
19 Finally, cells were coated with Bacto agarose and 2×DMEM in a fixed volume ratio
20
21 of 1:1 (supplemented with 10 μg/mL trypsin). The titer of PEDV was investigated by
22
23 plaque assay.³⁵
24
25
26
27

28
29 **2.9. Penetration assay.** After washing Vero cells with PBS, a PEDV inoculum (800
30
31 μL/well) was permitted to adhere to the cells for 2 h at 4 °C. Then the supernatant was
32
33 discarded, followed by two washes of the cells with PBS, addition of the mediums
34
35 containing different concentrations of Ag₂S NCs and the cells were cultured for an
36
37 additional 3 h to initiate viral penetration (37 °C/5% CO₂). Next, non-penetrated
38
39 virions were discarded by rinsing the cell monolayer twice with PBS, then the overlay
40
41 inoculum was added. The remaining steps were similar to those for attachment
42
43 assay.³⁶
44
45
46
47

48
49 **2.10. Viral negative-strand RNA replication.** After 2 h mock-treatment or
50
51 treatment with Ag₂S NCs, the Vero cells were treated with PEDV for 1 h, followed by
52
53 incubating separately with DMEM (containing 10 μg/mL trypsin) or Ag₂S NCs for 4,
54
55 5, 6 and 7 at 37 °C/5% CO₂. Total RNA was extracted and quantified by RT-PCR.
56
57
58
59
60

1
2
3
4 **2.11. Release analysis.** Vero cells were infected with PEDV at 0.01 MOI for 1 h
5
6 (37 °C/5% CO₂). Afterward, the infected cells were cultured in a 5% CO₂ incubator
7
8 for indicated infection periods of time, followed by mock-treatment or treatment with
9
10 Ag₂S NCs at 37 °C for 15, 30, 45 and 60 min. Next, the supernatant and cell lysate
11
12 were harvested and stored at -80 °C, respectively. Each sample was determined by
13
14 plaque assay in triplicate.³⁷
15
16

17
18 **2.12. Statistical analysis.** The experimental data was analyzed by an independent *t*
19
20 test. Statistical significance was decided with a **p* < 0.05 and ***p* < 0.01. Each data
21
22 point represents mean ± SD (N = 3).
23
24

25 26 **3. RESULTS**

27
28 **3.1. Characterization of Ag₂S NCs.** The optical properties, morphology and
29
30 chemical structure of the as-prepared Ag₂S NCs are shown in Figure 1. The maximum
31
32 emission wavelength of Ag₂S NCs at 681 and 722 nm with excitation at 450 nm
33
34 exhibited a red light emission. As shown in Figure 1a and 1e, no typical absorption
35
36 band of Ag nanoparticles or Ag (0) NCs were observed, indicating that Ag₂S NCs
37
38 rather than nanocrystals were formed at room temperature.³¹ This result was further
39
40 verified by measuring the powder X-ray diffraction (XRD) of Ag₂S NCs and no
41
42 distinct crystallinity was found (Figure 1d and 1h), which well supported the result of
43
44 UV-vis absorption spectra. Figure 1b and 1f show the characteristic TEM images of
45
46 the resultant Ag₂S NCs. It could be observed that these Ag₂S NCs (681 and 722 nm)
47
48 were spherical and greatly dispersible, and the average diameters were about 2.5 ± 0.6
49
50 and 4.1 ± 1.5 nm, respectively. Figure S1a presents the hydrodynamic size
51
52
53
54
55
56
57
58
59
60

distribution of Ag₂S NCs (681 nm), the average size was 3.7 nm which was determined by dynamic light scattering (DLS). Figure S1b shows that the average size of Ag₂S NCs (722 nm) was 5.3 nm.




Figure 1. (a and e) UV-vis and fluorescence spectrum of GSH-capped Ag₂S NCs (681 and 722 nm). (b and f) The TEM and HRTEM images of GSH-capped Ag₂S NCs (681 and 722 nm). (c and g) The FT-IR spectra of resultant GSH-capped Ag₂S NCs (681 and 722 nm) and GSH. (d and h) XRD patterns of resultant GSH-capped Ag₂S NCs (681 and 722 nm).

To further understand the characteristics of the as-prepared Ag₂S NCs, the surface functional groups and valence status of the Ag₂S NCs were performed. As shown in Figure 1c (681 nm) and Figure 1g (722 nm), the Ag₂S NCs displayed a typical peak at 3000~3500 cm⁻¹ and 785 cm⁻¹, ascribing to the stretching vibration of O-H (or N-H) and C-H. The peak around 1665 cm⁻¹ was attributed to the C=O vibration of the carboxylic acid groups on the surface of Ag₂S NCs. At 2,490 cm⁻¹, no apparent absorption peak for the free thiol group was observed at the same position, indicating that GSH molecules were connected with the surface of Ag₂S NCs through Ag-thiol bonds. The full range XPS analysis (Figure 2a and 2e) of the resultant Ag₂S sample

clearly showed four evident peaks at 163.1, 287.6, 367.7 and 531.6 eV, corresponding to S 2p, C 1s, Ag 3d and O 1s. A XPS spectrum of Ag 3d (Figure 2b and 2f) confirmed the presence of Ag(0) (367.7 eV). This revealed that Ag ions exist in the form of monovalent in Ag₂S NCs. The S 2p peaks at 163.1 and 161.7 eV were ascribed to S and Ag-S, respectively (Figure 2c and 2g).³⁸ The four fitted peaks at 284.6, 285.7, 287.6 and 288.2 eV in C 1s spectrum were assigned to -CH₂-CH₃, -CH-, -CONH₂ and -COOH groups, respectively (Figure 2d and 2h). The surface components of the Ag₂S NCs acquired by the XPS were in consistent with FT-IR results.




Figure 2. (a and e) XPS spectra of GSH-capped Ag₂S NCs (681 and 722 nm). High-resolution XPS spectra of Ag 3d (b and f), S 2p (c and g) and C 1s (d and h) of the Ag₂S NCs.

3.2. Toxicity of Ag₂S NCs on vero cells. The cytotoxicity of Ag₂S NCs on Vero cells was evaluated by determining cellular viability using an MTT and CCK-8 assay (Figure 3 and Figure S2). The viability of cells treated by Ag₂S NCs (681 nm) or GSH was measured at a concentration range of 23 to 184 μg/mL. As shown in Figure 3a and 3b, after cultivation for 24 and 48 h, the effect of 46 μg/mL Ag₂S NCs on cell

viability was inappreciable and the survival rate of Vero cells was over 90%. Meanwhile, the cell morphology was not influenced at this concentration (Figure 3c). When the concentration reached 184 $\mu\text{g/mL}$, the cytotoxicity of Ag_2S NCs was relatively low and the survival rate of Vero cells was about 68% after 48 h incubation. Gui et al. reported the cell viability far exceeded 91% after treatment with QDs for 48 h, at a Ag_2S QDs exposure concentration of 1.0 mg/mL, which was similar to our present study.²⁵ Hence, 46 $\mu\text{g/mL}$ was applied for the subsequent tests.




Figure 3. Cytotoxicity of different concentrations of Ag_2S NCs (681 nm) by MTT (a) and CCK-8 (b) assay. (c) Vero cell morphology after incubation with different concentrations of Ag_2S NCs (23-184 $\mu\text{g/mL}$) and 10 mM GSH.

3.3. Influence of Ag_2S NCs on PEDV replication. One-step growth curve was plotted to detect the PEDV titer after treatment with 46 $\mu\text{g/mL}$ Ag_2S NCs to evaluate the effect of Ag_2S NCs on PEDV replication. In Figure 4a, compared to the negative control group, significant viral titer inhibition was observed in cells treated with Ag_2S

NCs. When treated with Ag₂S NCs at 12 hpi, the plaque formation unit (PFU) was significantly decreased from 3.8×10^5 to 2.5×10^2 PFU/mL as shown by the results from Figure 4b. Therefore, the number of plaques and the titer of virus verified that Ag₂S NCs indeed possesses excellent antiviral activity against viral replication.




Figure 4. Growth curves of viruses after treatment or untreated with Ag₂S NCs.

Cells were infected with PEDV for the indicated periods of time (a). Plaque-reduction assay after neutral red staining. Pictures were taken 2-3 days following infection (b).

Each data point represents mean \pm SD (N = 3).

PEDV nucleocapsid (N), the RNA-binding protein, acts a vital role in the viral life cycle, and can serve as a target for precise and early diagnosis of PEDV infection.³⁹

To validate the inhibitory effect of Ag₂S NCs on the proliferation of PEDV, the expression level of PEDV N protein was detected. Briefly, the infected cells were incubated with different concentrations of Ag₂S NCs or control DMEM (including 10 μ g/mL trypsin). After 12 hpi, the cells treated with Ag₂S NCs at different concentrations showed an obvious difference in the number of infected cells (indicated via green fluorescence) compared to the untreated PEDV-infected group (Figure 5). This indicated that the expression of PEDV N protein was continuously down-regulated in a concentration-dependent manner, which was consistent with the growth curves of virus.





Figure 5. Indirect immunofluorescence assay of PEDV-infected Vero cells after treatment or untreated with different concentrations of Ag₂S NCs. Scale bar: 100 μm.

3.4. Effect of Ag₂S NC size on the multiplication of PEDV. As is well-known to all, the size of nanoparticles plays an indispensable role in their interactions with external systems.^{40,41} To further characterize the potential influence of the size on the multiplication of PEDV, we tested the interaction of Ag₂S NCs-681 (Ag₂S NCs-S) and Ag₂S NCs-722 (Ag₂S NCs-L) with PEDV by a plaque formation assay. As shown in Figure 6b, when compared to untreated cells, the virus titer in the cells treated with Ag₂S NCs-S and Ag₂S NCs-L was significantly reduced by 2.4 log and 3.0 log, respectively, and this result is more intuitively shown in Figure S3. To further illustrate the differences of viral multiplication at the protein level, the expression of PEDV N protein after treatment with Ag₂S NCs-S and Ag₂S NCs-L was measured by indirect immunofluorescence assay and western blot assay. The green fluorescence

1
2
3
4 signal of the group exposed with Ag₂S NCs-S or Ag₂S NCs-L was obviously reduced
5
6 compared with the control, and the Ag₂S NCs-S-treated group had a more pronounced
7
8 decrease tendency than the Ag₂S NCs-L-treated group (Figure 6a). The western blot
9
10 assay indicated that the number of PEDV N protein expression was significantly
11
12 down-regulated compared with that of the control after treatment with Ag₂S NCs-S or
13
14 Ag₂S NCs-L (Figure 6c). The overall results indicated that Ag₂S NCs-S-treated group
15
16 had a pronounced inhibition on PEDV infection and excluded the possibility that the
17
18 aforementioned plaque reductions were arised from cytotoxicity of the Ag₂S NCs.
19
20 Interestingly, the results were similar to those reported by our group about the effects
21
22 of different sizes of CdTe quantum dots on pseudorabies virus.⁴² In general, smaller
23
24 nanoparticles cause weaker hydrodynamic and shear force when they entry into the
25
26 cell, which make them penetrate deeper than the larger nanoparticles.^{41,43,44} This may
27
28 be the reason that lead to a better antiviral effect of small size Ag₂S NCs.
29
30
31
32
33
34



51 **Figure 6.** The effect of Ag₂S NCs-S and Ag₂S NCs-L on PEDV. (a) Indirect
52
53 immunofluorescence assay of PEDV-infected Vero cells after treatment or
54
55 untreated with Ag₂S NCs-S and Ag₂S NCs-L. Scale bar: 100 μm. (b) The titer of
56
57
58
59
60

1
2
3 PEDV in the presence and absence of Ag₂S NCs-S and Ag₂S NCs-L. (c) Detection of
4
5 PEDV-N protein expression through western blot assay. The infected cells were
6
7 exposed with Ag₂S NCs-S and Ag₂S NCs-L for 12 hpi. β-actin was used as a loading
8
9 control.
10
11

12
13 **3.5. Effect of Ag⁺ and S²⁻ on the multiplication of PEDV.** To probe the effect of
14
15 release of Ag⁺ from Ag₂S NCs on viral replication, infected cells were exposed with
16
17 various concentrations of Ag⁺. After incubation of 24 hpi, the results showed that 4.8
18
19 ± 1.3 μM Ag⁺ was released when PEDV was exposed with 46 μM Ag₂S NCs, which
20
21 was quantitative detection through Inductively Coupled Plasma Mass Spectrometry
22
23 (ICP-MS). In Figure S4a, green fluorescence signals of the group treated with
24
25 different concentrations of Ag⁺ were not significantly decreased compared with the
26
27 PEDV-infected control, which was further verified by Figure S4b. In addition, the
28
29 effects of different concentrations of S²⁻ (K_{sp} (Ag₂S) = 6 × 10⁻⁵⁰) on viral replication
30
31 were also investigated. From Figure S4c and S4d, it can be seen that the results were
32
33 similar to the aforementioned ones, suggesting the release of Ag⁺ and S²⁻ from Ag₂S
34
35 NCs cannot play a dominate role in the antiviral ability of Ag₂S NCs.
36
37
38
39
40
41

42
43 **3.6. Effect of Ag₂S NCs on PEDV replication cycle.** The replication cycle of
44
45 viruses consists of the four consecutive steps of attachment, penetration, replication
46
47 and budding. To further elucidate the mechanism of Ag₂S NCs to inhibit PEDV
48
49 infection, we performed a series of tests to recognize which step(s) in the life cycle of
50
51 the virus was inhibited by Ag₂S NCs.
52
53

54
55 To test whether Ag₂S NCs could inhibit PEDV binding to cells, the impact of Ag₂S
56
57
58
59
60

1
2
3 NCs on the attachment was estimated by plaque assay. Briefly, the cells were first
4
5
6 exposed with different concentrations of Ag₂S NCs and then infected by 0.03 MOI
7
8 PEDV at 4 °C for 2 h to allow virus attachment. Infected cells untreated with Ag₂S
9
10 NCs were used as controls. As shown in Figure 7 and Figure S5, the number of
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

plaques after treatment with Ag₂S NCs was similar to that of the control, suggesting that Ag₂S NCs did not inhibit the viral attachment nor the virus in the early-infection phase. This result also suggested that before viral entry into the cells, Ag₂S NCs did not significantly inhibit PEDV infection by inactivating PEDV directly.




Figure 7. A dose-response study on the relationship between the inhibition efficiency of viral attachment and the amount of Ag₂S NCs.

To investigate whether Ag₂S NCs can inhibit viral penetration, PEDV was incubated with the cells at 4 °C for 2 h to allow the virus to attach to the cell surface, followed by initiation of the penetration process by shifting temperature to 37 °C. In Figure 8, there was no remarkable decrease in PEDV titer with the increase of Ag₂S NCs concentration. Meanwhile, no significant plaque-number difference was detected after treatment or untreated with Ag₂S NCs (Figure S6), suggesting that the Ag₂S

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

NCs had no impact on the process of penetration of the virus on the cell surface. The process of viral entry into host cells involves the recognition between the viral envelope glycoproteins and the cell surface receptors. According to this mechanism, AgNPs modified with mercaptoethane sulfonate can inhibit the virus proliferation by blocking the binding of the virus to cell surface heparin.⁴⁵ Owing to the absence of molecules that bind to the virus on the surface of the Ag₂S NCs, the binding of virus to the cell surface receptor cannot be prevented.




Figure 8. A dose-response study on the relationship between the inhibition efficiency of viral penetration and the amount of Ag₂S NCs.

To investigate the effects of Ag₂S NCs on the replication step of PEDV, the level of negative-strand RNA of PEDV was tested. Briefly, Vero cells were unexposed or exposed with Ag₂S NCs for 2 h, followed by infecting the cells separately with PEDV for 4, 5, 6 and 7 h. As shown in Figure 9, the synthesis of negative-strand RNA of PEDV was dramatically down-regulated at different hours post infection, compared with the control groups. These results clearly demonstrated the inhibition of Ag₂S NCs on PEDV replication.




Figure 9. The relative synthesis of negative-strand RNA of PEDV was determined at different hours post infection, with Vero cells mock-treated or treated with Ag₂S NCs.

The virion nucleocapsid successfully released into the cytoplasm of host cell after viral proteins were synthesized and assembled, then progeny virions could bud from the plasma membrane on the surface of the infected cell. To determine whether the Ag₂S NCs could influence the virion budding, cells were first treated with PEDV for the indicated time periods and then mock-treatment or treatment with Ag₂S NCs for 15, 30, 45 and 60 min. After the infected cells were treated with Ag₂S NCs for different time points, the virus titers in the Ag₂S NCs-treated group were significantly decreased compared with the control groups (Figure 10). This indicated that even if the cells have been infected with PEDV, the subsequent Ag₂S NCs treatment was still effective in inhibiting viral budding.




Figure 10. Quantification of the titer of PEDV after the treatment of Ag₂S NCs for a different time point. The virus titer of intracellular (a) and supernatant (b).

3.7. Ag₂S NCs activate antiviral innate immunity. To further probe the potential mechanism of Ag₂S NCs inhibition of PEDV infection, we estimated the impact of Ag₂S NCs on the immune and inflammation response of the host interferon. As previously reported, type I interferons (IFNs) and IFN-stimulated genes (ISGs) were the most famous antiviral innate immune molecules.^{46,47} The induction of ISGs and pro-inflammatory cytokines required the coordination and synergy effects of the transcription factors IRF3 and NF- κ B. In order to explore whether Ag₂S NCs promoted the production of IRF-3 and NF- κ B, cells were co-transfected with the IRF3-Luc and NF- κ B-Luc luciferase reporter plasmids along with the internal control plasmid pRL-TK after unexposure or exposure with Ag₂S NCs. As displayed in Figure 11, the Ag₂S NCs positively regulated the promoter activity of IRF3 and NF- κ B. Meanwhile, production of IRF3 and NF- κ B is often marked by the phosphorylation of IRF3 and NF- κ B subunit p65, respectively. As expected, when compared with the control, Ag₂S NCs treatment obviously enhanced IRF3 and p65 phosphorylation (Figure 11c and 11d), which were concordant with the findings of the

Luciferase tests.





Figure 11. Ag₂S NCs promoted the activation of IRF3 and NF-κB promoter. Vero cells were co-transfected with the IRF3-Luc (a) and NF-κB-Luc (b) along with the pRL-TK plasmid. Luciferase assay was performed after the treatment of Ag₂S NCs for 12 hours. (c and d) Ag₂S NCs treatment induced phosphorylation of IRF3 and p65. Cells were exposed with Ag₂S NCs for 12 h and harvested for western blot analysis with phosphorylated IRF3 (p-IRF3), IRF3, phosphorylated p65 (p-p65), p65 or β-actin antibodies.

The mRNA expression levels of ISGs and pro-inflammatory cytokines were determined by real-time RT-PCR. Compared with the control group, the levels of mRNA expression levels of interferon-stimulated genes 20 (ISG-20) and 54 (ISG-54) were increased. Furthermore, the expressions of pro-inflammatory cytokines were also significantly upregulated after the treatment of Ag₂S NCs, and the mRNA expressions of interleukin 8 (IL-8) and interleukin 6 (IL-6) were 9.3- and 3.3-times

1
2
3
4 higher than that of the untreated controls (Figure 12). It is reported that IL-8
5
6 upregulation might cause IL-8 recruited neutrophils to phagocytose target antigens,
7
8 thereby regulating virus replication by triggering Toll-like receptors and activating the
9
10 IFN- β and ISG.⁴⁸ Meanwhile, Yu et al. found that fish TRIM32 could inhibit virus
11
12 infection by up-regulating the interferon immune response, IL-6 and IL-8.⁴⁹ It was
13
14 also reported that ISG-20 could inhibit the synthesis of virus RNA by inhibiting the
15
16 enzymatic activities.⁵⁰ Additionally, ISG-54 was reported to stimulate the expression
17
18 of phosphorylated STAT1, which would play a crucial part in the immune and
19
20 inflammatory responses.^{51,52} These reports suggested that the production of ISGs and
21
22 the up-regulation of pro-inflammatory cytokines might have a crucial role in the
23
24 inhibitory effect of Ag₂S NCs. Yet, the results could not exclude the probability of
25
26 exploiting other antiviral activity mechanism(s).
27
28
29
30
31
32



33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56 **Figure 12.** The level of cytokines expression in Vero cells after exposure with 46
57
58
59
60

1
2
3
4 $\mu\text{g/mL}$ Ag_2S NCs. The expressions of ISG-20 (a), ISG-54 (b), IL-8 (c) and IL-6 (d)
5
6 were detected by real-time RT-PCR assay.
7

8 **4. DISCUSSION**

9

10
11 Currently, the antiviral therapies are focused on the following two strategies. Firstly,
12
13 viral infection starts from the virion adhesion or binding to the host's receptors,
14
15 followed by penetration and viral replication.⁵³ So, effective blocking of viral
16
17 attachment and entry into the cell can have a remarkable prophylactic effect against
18
19 viral diseases.^{54,55} The other strategy is concentrated on inhibition of viral replication
20
21 and budding (therapeutic effect).⁵⁶
22
23

24
25 For the antiviral activity, the most widely studied materials include Ag
26
27 nanoparticles and Au nanoparticles,^{57,58} carbon-based materials,⁵⁹ silicon
28
29 nanoparticle⁶⁰ and so on.^{61,62} In vitro studies have shown that functional AgNPs (or
30
31 Au nanoparticles) could be acted as drugs against human immunodeficiency virus
32
33 type 1 (HIV-1),⁶³ herpes simplex virus type 1(HSV-1),⁶⁴ tacaribe virus (TCRV),
34
35 respiratory syncytial virus (RSV) and so on. Lee et al. constructed the GAG mimetic
36
37 functionalised silica nanoparticles that can be used as viral entry inhibitors by
38
39 blocking viral attachment and penetration into cells.⁶⁵ Yang et al. reported that
40
41 functionalized graphene showed highly efficient inhibition on RSV infection by
42
43 directly inactivating the virus.⁶⁶ Zhu's group found that AgNPs@OTV could suppress
44
45 H1N1 influenza virus infection via ROS-mediated signaling pathways.⁶⁷ Furthermore,
46
47 Yang et al. have shown that AgNPs could inhibit the RSV titers by two orders of
48
49 magnitude based on a tissue culture infectious dose (TCID₅₀) assay.²⁰
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 The level of PEDV N protein expression was also checked through western blot
5
6 assay after Vero cells were unexposed or exposed with the same concentration of
7
8 Ag₂S NCs and AgNCs. In Figure S7, Ag₂S NCs showed a stronger inhibitory effect
9
10 than AgNCs. Moreover, it was reported that DNA-modified gold nanoparticle
11
12 networks can impede viral attachment and entry into cells for prophylactic effects, and
13
14 these composite can also produce therapeutic effects.⁵⁶ Meanwhile, our previous study
15
16 proved that CDs can suppress porcine reproductive and respiratory syndrome virus
17
18 (PRRSV) and pseudorabies virus (PRV) proliferation through activating the production
19
20 of interferon- α production and interferon stimulated genes.⁶⁸ Additionally, our
21
22 previous work also demonstrated that CdTe quantum dots suppress PRV proliferation
23
24 by altering the structure of viral surface proteins and the leakage of Cd²⁺.⁴² We
25
26 speculate that nanoparticles with a different composition vary in their antiviral
27
28 mechanism. To further illustrate the antiviral mechanism of Ag₂S NCs, we
29
30 investigated the effect of Ag₂Te NPs with a different composition on PEDV by
31
32 comparing the expression of PEDV N proteins after treatment with various
33
34 concentrations of Ag₂Te NPs. In Figure S8, Ag₂Te NPs did not exhibit obvious
35
36 antiviral activity against PEDV, implying that the main antiviral activity of Ag₂S NCs
37
38 was not dependent on Ag⁺.
39
40
41
42
43
44
45
46

47 The antiviral potential of Ag₂S NCs was further evaluated by using another RNA
48
49 virus, PRRSV (a member of *Arteriviridae*). Consistent with the result for PEDV, Ag₂S
50
51 NCs also displayed inhibitory effects on the expression level of the PRRSV viral
52
53 protein (Figure S9). Thus, it can be deduced that Ag₂S NCs might have
54
55
56
57
58
59
60

1
2
3 broad-spectrum antiviral properties against RNA viruses.
4

5. CONCLUSION

5
6

7
8 In summary, this study described a one-pot method to prepare hydrosoluble and
9 biocompatible GSH capped-Ag₂S NCs. We demonstrated for the first time that Ag₂S
10 NCs had remarkable antiviral activity against PEDV infection, with the infection
11 inhibited for a 3.0 log reduction in virus titer at the noncytotoxic concentration at 12
12 hpi. The study of underlying molecular mechanisms indicated that Ag₂S NCs
13 treatment inhibits the synthesis of viral negative-strand RNA and viral budding.
14 Furthermore, we also found that Ag₂S NCs activated the production of
15 IFN-stimulating genes (ISGs) and the expression of pro-inflammation cytokines of
16 Vero cells, which might inhibit the PEDV infection.
17
18
19
20
21
22
23
24
25
26
27
28
29

30 These inspiring findings offer experimental support for the further exploitation of
31 Ag₂S NCs as a potential and highly effective antiviral agent *in vivo*. Given that SARS,
32 MARS and PEDV belong to the coronavirus family, our results suggest the possibility
33 to develop efficient anti-SARS or anti-MARS reagents based on Ag₂S NCs or
34 conjugation of Ag₂S NCs and functional molecules.
35
36
37
38
39
40
41
42

ASSOCIATED CONTENT

43

Supporting Information

44
45

46 Supplementary data can be found in Supporting Information. Supplementary data
47 including: cytotoxicity; plaque assay; western blot; indirect immunofluorescence
48 assay and primers sequence.
49
50
51
52
53

AUTHOR INFORMATION

54
55
56
57
58
59
60

Corresponding Authors

*E-mail: hyhan@mail.hzau.edu.cn;

*E-mail: vet@mail.hzau.edu.cn.

*These authors jointly supervised this work.

Notes

The authors declare no competing financial interests.

ACKNOWLEDGMENTS

We gratefully acknowledge the support for this research by the National Key R & D Program (2016YFD0500700) and the National Natural Science Foundation of China (21375043, 31672569, 21778020).

REFERENCES

- (1) Lin, Z.; Li, Y.; Guo, M.; Xu, T.; Wang, C.; Zhao, M.; Wang, H.; Chen, T.; Zhu, B. The Inhibition of H1N1 Influenza Virus-Induced Apoptosis by Silver Nanoparticles Functionalized with Zanamivir. *RSC Adv.* **2017**, *7*, 742-750.
- (2) Rogers, J.V.; Parkinson, C.V.; Choi, Y.W.; Speshock, J.L.; Hussain, S.M. A Preliminary Assessment of Silver Nanoparticle Inhibition of Monkeypox Virus Plaque Formation. *Nanoscale Res. Lett.* **2008**, *3*, 129-133.
- (3) Elechiguerra, J.L.; Burt, J.L.; Morones, J.R.; Camacho Bragado, A.; Gao, X.; Lara, H.H.; Yacaman, M.J. Interaction of Silver Nanoparticles with HIV-1. *J. Nanobiotech.* **2005**, *3*, 6-16.
- (4) Papp, I.; Sieben, C.; Ludwig, K.; Roskamp, M.; Bottcher, C.; Schlecht, S.; Herrmann, A.; Haag, R. Inhibition of Influenza Virus Infection by Multivalent

- 1
2
3 Sialic-Acid-Functionalized Gold Nanoparticles. *Small* **2010**, *6*, 2900-2906.
- 4
5
6 (5) Draz, M.S.; Wang, Y.J.; Chen, F.F.; Xu, Y.; Shafiee, H. Electrically Oscillating
7
8 Plasmonic Nanoparticles for Enhanced DNA Vaccination Against Hepatitis C
9
10 Virus. *Adv. Funct. Mater.* **2017**, *27*, 1604139-1604149.
- 11
12
13 (6) Barras, A.; Pagneux, Q.; Sane, F.; Wang, Q.; Boukherroub, R.; Hober, D.;
14
15 Szunerits, S. High Efficiency of Functional Carbon Nanodots as Entry Inhibitors
16
17 of Herpes Simplex Virus Type 1. *ACS Appl. Mater. Interfaces* **2016**, *8*, 9004-9013.
- 18
19
20 (7) Muñoz, A.; Sigwalt, D.; Illescas, B.M.; Luczkowiak, J.; Rodríguez-Pérez, L.;
21
22 Nierengarten, I.; Holler, M.; Remy, J.S.; Buffet, K.; Vincent, S.P.; Rojo, J.;
23
24 Delgado, R.; Nierengarten, J.F.; Martín, N. Synthesis of Giant Globular
25
26 Multivalent Glycofullerenes as Potent Inhibitors in a Model of Ebola Virus
27
28 Infection. *Nat. Chem.* **2015**, *8*, 50-57.
- 29
30
31 (8) Sametband, M.; Kalt, I.; Gedanken, A.; Sarid, R. Herpes Simplex Virus Type-1
32
33 Attachment Inhibition by Functionalized Graphene Oxide. *ACS Appl. Mater.*
34
35 *Interfaces* **2014**, *6*, 1228-1235.
- 36
37
38 (9) Ziem, B.; Rahn, J.; Donskyi, I.; Silberreis, K.; Cuellar, L.; Dervedde, J.; Keil, G.;
39
40 Mettenleiter, T.C.; Haag, R. Polyvalent 2D Entry Inhibitors for Pseudorabies and
41
42 African Swine Fever Virus. *Macromol. Biosci.* **2017**, *17*, 1600499-1600508.
- 43
44
45 (10) Deokar, A.R.; Nagvenkar, A.P.; Kalt, I.; Shani, L.; Yeshurun, Y.; Gedanken, A.;
46
47 Sarid, R. Graphene-Based "Hot Plate" for the Capture and Destruction of the
48
49 Herpes Simplex Virus Type 1. *Bioconjugate Chem.* **2017**, *28*, 1115-1122.
- 50
51
52 (11) Wang, J.; Liu, Y.; Xu, K.; Qi, Y.; Zhong, J.; Zhang, K.; Li, J.; Wang, E.; Wu, Z.;
53
54
55
56
57
58
59
60

- 1
2
3 Kang, Z. Broad-Spectrum Antiviral Property of Polyoxometalate Localized on a
4 Cell Surface. *ACS Appl. Mater. Interfaces* **2014**, *6*, 9785-9789.
5
6
7
8
9 (12) Bhatia, S.; Lauster, D.; Bardua, M.; Ludwig, K.; Angioletti Uberti, S.; Popp, N.;
10 Hoffmann, U.; Paulus, F.; Budt, M.; Stadtmuller, M.; Wolff, T.; Hamann, A.;
11 Bottcher, C.; Herrmann, A.; Haag, R. Linear Polysialoside Outperforms
12 Dendritic Analogs for Inhibition of Influenza Virus Infection in Vitro and in Vivo.
13 *Biomaterials* **2017**, *138*, 22-34.
14
15
16
17
18
19
20 (13) Liang, J.J.; Wei, J.C.; Lee, Y.L.; Hsu, S.H.; Lin, J.J.; Lin, Y.L.
21 Surfactant-Modified Nanoclay Exhibits an Antiviral Activity with High Potency
22 and Broad Spectrum. *J. Virol.* **2014**, *88*, 4218-4228.
23
24
25
26
27
28 (14) Osminkina, L.A.; Timoshenko, V.Y.; Shilovsky, I.P.; Kornilaeva, G.V.;
29 Shevchenko, S.N.; Gongalsky, M.B.; Tamarov, K.P.; Abramchuk, S.S.; Nikiforov,
30 V.N.; Khaitov, M.R.; Karamov, E.V. Porous Silicon Nanoparticles as Scavengers
31 of Hazardous Viruses. *J. Nanopart. Res.* **2014**, *16*, 2430-2440.
32
33
34
35
36
37
38 (15) Douglas, J.L.; Panis, M.L.; Ho, E.; Lin, K.Y.; Krawczyk, S.H.; Grant, D.M.; Cai,
39 R.; Swaminathan, S.; Cihlar, T. Inhibition of Respiratory Syncytial Virus Fusion
40 by the Small Molecule VP-14637 via Specific Interactions with F Protein. *J.*
41 *Virol.* **2003**, *77*, 5054-5064.
42
43
44
45
46
47
48 (16) Yang, J.; Li, M.; Shen, X.; Liu, S. Influenza A Virus Entry Inhibitors Targeting
49 the Hemagglutinin. *Viruses* **2013**, *5*, 352-373.
50
51
52
53 (17) Lauster, D.; Glanz, M.; Bardua, M.; Ludwig, K.; Hellmund, M.; Hoffmann, U.;
54 Hamann, A.; Bottcher, C.; Haag, R.; Hackenberger, C.P.R.; Herrmann, A.
55
56
57
58
59
60

- 1
2
3 Multivalent Peptide-Nanoparticle Conjugates for Influenza-Virus Inhibition.
4
5
6 *Angew. Chem.* **2017**, *56*, 5931-5936.
7
- 8 (18) Khanal, M.; Vausselin, T.; Barras, A.; Bande, O.; Turcheniuk, K.; Benazza, M.;
9
10 Zaitsev, V.; Teodorescu, C.M.; Boukherroub, R.; Siriwardena, A.; Dubuisson, J.;
11
12 Szunerits, S. Phenylboronic-Acid-Modified Nanoparticles: Potential Antiviral
13
14 Therapeutics. *ACS Appl. Mater. Interfaces* **2013**, *5*, 12488-12498.
15
16
- 17 (19) Khanal, M.; Barras, A.; Vausselin, T.; Feneant, L.; Boukherroub, R.; Siriwardena,
18
19 A.; Dubuisson, J.; Szunerits, S. Boronic Acid-Modified Lipid Nanocapsules: a
20
21 Novel Platform for the Highly Efficient Inhibition of Hepatitis C Viral Entry.
22
23 *Nanoscale* **2015**, *7*, 1392-1402.
24
25
- 26 (20) Yang, X.X.; Li, C.M.; Huang, C.Z. Curcumin Modified Silver Nanoparticles for
27
28 Highly Efficient Inhibition of Respiratory Syncytial Virus Infection. *Nanoscale*
29
30
31 **2016**, *8*, 3040-3048.
32
33
- 34 (21) Ye, S.; Shao, K.; Li, Z.; Guo, N.; Zuo, Y.; Li, Q.; Lu, Z.; Chen, L.; He, Q.; Han,
35
36 H. Antiviral Activity of Graphene Oxide: How Sharp Edged Structure and
37
38 Charge Matter. *ACS Appl. Mater. Interfaces* **2015**, *7*, 21571-21579.
39
40
- 41 (22) Wang, D.; Fang, L.; Shi, Y.; Zhang, H.; Gao, L.; Peng, G.; Chen, H.; Li, K.; Xiao,
42
43 S. Porcine Epidemic Diarrhea Virus 3C-Like Protease Regulates its Interferon
44
45 Antagonism by Cleaving NEMO. *J. Virol.* **2015**, *90*, 2090-2101.
46
47
48
- 49 (23) Ding, Z.; Fang, L.; Jing, H.; Zeng, S.; Wang, D.; Liu, L.; Zhang, H.; Luo, R.;
50
51 Chen, H.; Xiao, S. Porcine Epidemic Diarrhea Virus Nucleocapsid Protein
52
53 Antagonizes Beta Interferon Production by Sequestering the Interaction between
54
55
56
57
58
59
60

- 1
2
3 IRF3 and TBK1. *J. Virol.* **2014**, *88*, 8936-8945.
- 4
5
6 (24) Du, Y.; Xu, B.; Fu, T.; Cai, M.; Li, F.; Zhang, Y.; Wang, Q. Near-Infrared
7
8 Photoluminescent Ag₂S Quantum Dots from a Single Source Precursor. *J. Am.*
9
10
11 *Chem. Soc.* **2010**, *132*, 1470-1471.
- 12
13 (25) Gui, R.; Wan, A.; Liu, X.; Yuan, W.; Jin, H. Water-Soluble Multidentate Polymers
14
15 Compactly Coating Ag₂S Quantum Dots with Minimized Hydrodynamic Size
16
17 and Bright Emission Tunable from Red to Second Near-Infrared Region.
18
19
20
21 *Nanoscale* **2014**, *6*, 5467-5473.
- 22
23 (26) Zhang, Y.; Hong, G.; Zhang, Y.; Chen, G.; Li, F.; Dai, H.; Wang, Q. Ag₂S
24
25 Quantum Dot: a Bright and Biocompatible Fluorescent Nanoprobe in the Second
26
27 Near-Infrared Window. *ACS Nano* **2012**, *6*, 3695-3702.
- 28
29
30 (27) Tan, L.; Wan, A.; Li, H. Conjugating S-nitrosothiols with Glutathione Stabilized
31
32 Silver Sulfide Quantum Dots for Controlled Nitric Oxide Release and
33
34 Near-Infrared Fluorescence Imaging. *ACS Appl. Mater. Interfaces* **2013**, *5*,
35
36
37
38
39 11163-11171.
- 40 (28) Tang, R.; Xue, J.; Xu, B.; Shen, D.; Sudlow, G.P.; Achilefu, S.; Tunable
41
42 Ultrasmall Visible-to-Extended Near-Infrared Emitting Silver Sulfide Quantum
43
44 Dots for Integrin-Targeted Cancer Imaging. *ACS Nano* **2015**, *9*, 220-230.
- 45
46
47 (29) Yang, T.; Tang, Y.; Liu, L.; Lv, X.; Wang, Q.; Ke, H.; Deng, Y.; Yang, H.; Yang,
48
49
50
51
52
53
54
55
56
57
58
59
60 X.; Liu, G.; Zhao, Y.; Chen, H. Size-Dependent Ag₂S Nanodots for Second
Near-Infrared Fluorescence/Photoacoustics Imaging and Simultaneous
Photothermal Therapy. *ACS Nano* **2017**, *11*, 1848-1857.

- 1
2
3
4 (30) Miao, P.; Tang, Y.; Wang, B.; Meng, F. Near-Infrared Ag₂S Quantum Dots-Based
5
6 DNA Logic Gate Platform for miRNA Diagnostics. *Anal. Chem.* **2016**, *88*,
7
8 7567-7573.
9
- 10
11 (31) Wang, C.; Wang, Y.; Xu, L.; Zhang, D.; Liu, M.; Li, X.; Sun, H.; Lin, Q.; Yang, B.
12
13 Facile Aqueous-Phase Synthesis of Biocompatible and Fluorescent Ag₂S
14
15 Nanoclusters for Bioimaging: Tunable Photoluminescence from Red to Near
16
17 Infrared. *Small* **2012**, *8*, 3137-3142.
18
19
- 20
21 (32) Liu, A.A.; Zhang, Z.; Sun, E.Z.; Zheng, Z.; Zhang, Z.L.; Hu, Q.; Wang, H.; Pang,
22
23 D.W. Simultaneous Visualization of Parental and Progeny Viruses by a
24
25 Capsid-Specific Halo Tag Labeling Strategy. *ACS Nano* **2016**, *10*, 1147-1155.
26
27
- 28
29 (33) Huang, B.H.; Lin, Y.; Zhang, Z.L.; Zhuan, F.; Liu, A.A.; Xie, M.; Tian, Z.Q.;
30
31 Zhang, Z.; Wang, H.; Pang, D.W. Surface Labeling of Enveloped Viruses
32
33 Assisted by Host Cells. *ACS Chem. Biol.* **2012**, *7*, 683-688.
34
- 35
36 (34) Luo, R.; Fang, L.; Jin, H.; Jiang, Y.; Wang, D.; Chen, H.; Xiao, S. Antiviral
37
38 Activity of Type I and Type III Interferons Against Porcine Reproductive and
39
40 Respiratory Syndrome Virus (PRRSV). *Antivir. Res.* **2011**, *91*, 99-101.
41
42
- 43
44 (35) Alvarez, A. L.; Melon, S.; Dalton, K. P.; Nicieza, I.; Roque, A.; Suarez, B.; Parra,
45
46 F. Apple Pomace, a by-Product From the Asturian Cider Industry, Inhibits Herpes
47
48 Simplex Virus Types 1 and 2 in Vitro Replication: Study of its Mechanisms of
49
50 Action. *J. Med. Food* **2012**, *15*, 581-587.
51
- 52
53 (36) Gescher, K.; Hensel, A.; Hafezi, W.; Derksen, A.; Kuhn, J. Oligomeric
54
55 Proanthocyanidins from *Rumex Acetosa* L. Inhibit the Attachment of Herpes
56
57
58
59
60

- 1
2
3 Simplex Virus Type-1. *Antivir. Res.* **2011**, *89*, 9-18.
4
5
6 (37) Duan, E.; Wang, D.; Fang, L.; Ma, J.; Luo, J.; Chen, H.; Li, K.; Xiao, S.
7
8 Suppression of Porcine Reproductive and Respiratory Syndrome Virus
9
10 Proliferation by Glycyrrhizin. *Antivir. Res.* **2015**, *120*, 122-125.
11
12
13 (38) Wang, Y.; Yan, X.P. Fabrication of Vascular Endothelial Growth Factor Antibody
14
15 Bioconjugated Ultrasmall Near-Infrared Fluorescent Ag₂S Quantum Dots for
16
17 Targeted Cancer Imaging in Vivo. *Chem. Commun.* **2013**, *49*, 3324-3326.
18
19
20 (39) Xu, X.; Zhang, H.; Zhang, Q.; Huang, Y.; Dong, J.; Liang, Y.; Liu, H.J.; Tong, D.
21
22 Porcine Epidemic Diarrhea Virus N Protein Prolongs S-Phase Cell Cycle,
23
24 Induces Endoplasmic Reticulum Stress, and Up-Regulates Interleukin-8
25
26 Expression. *Vet. Microbiol.* **2013**, *164*, 212-221
27
28
29 (40) Winnik, F.M.; Maysinger, D. Quantum Dot Cytotoxicity and Ways to Reduce it.
30
31
32 *Accounts Chem. Res.* **2013**, *46*, 672-680.
33
34
35 (41) Kan-Davelaar van, H.E.; Hest van, J.C.M.; Cornelissen, J.J.L.M.; Koay, M.S.T.
36
37 Using Viruses as Nanomedicines. *Brit. J. Pharmacol.* **2014**, *171*, 4001-4009.
38
39
40 (42) Du, T.; Cai, K.; Han, H.; Fang, L.; Liang, J.; Xiao, S. Probing the Interactions of
41
42 CdTe Quantum Dots with Pseudorabies Virus. *Sci. Rep.* **2015**, *5*, 16403.
43
44
45 (43) Hao, J.; Huang, L.L.; Zhang, R.; Wang, H.Z.; Xie, H.Y. A Mild and Reliable
46
47 Method to Label Enveloped Virus with Quantum Dots by Copper-Free Click
48
49 Chemistry. *Anal. Chem.* **2012**, *84*, 8364-8370.
50
51
52 (44) Zhang, P.; Liu, S.; Gao, D.; Hu, D.; Gong, P.; Sheng, Z.; Deng, J.; Ma, Y.; Cai, L.
53
54 Click-Functionalized Compact Quantum Dots Protected by
55
56
57
58
59
60

- 1
2
3
4 Multidentate-Imidazole Ligands: Conjugation-Ready Nanotags for Living-Virus
5
6 Labeling and Imaging. *J. Am. Chem. Soc.* **2012**, *134*, 8388-8391.
7
8
9 (45) Baram-Pinto, D.; Shukla, S.; Perkas, N.; Gedanken, A.; Sarid, R. Inhibition of
10
11 Herpes Simplex Virus Type 1 Infection by Silver Nanoparticles Capped with
12
13 Mercaptoethane Sulfonate. *Bioconjugate Chem.* **2009**, *20*, 1497-1502.
14
15
16 (46) Fensterl, V.; Sen, G.C. Interferon-Induced I Fit Proteins: Their Role in Viral
17
18 Pathogenesis. *J. Virol.* **2015**, *89*, 2462-2468.
19
20
21 (47) Schoggins, J.W.; Wilson, S.J.; Panis, M.; Murphy, M.Y.; Jones, C.T.; Bieniasz, P.;
22
23 Rice, C.M. A Diverse Range of Gene Products are Effectors of the Type I
24
25 Interferon Antiviral Response. *Nature* **2011**, *472*, 481-485.
26
27
28 (48) Tokumoto, Y.; Hiasa, Y.; Uesugi, K.; Watanabe, T.; Mashiba, T.; Abe, M.;
29
30 Kumagi, T.; Ikeda, Y.; Matsuura, B.; Onji, M. Ribavirin Regulates Hepatitis C
31
32 Virus Replication through Enhancing Interferon-Stimulated Genes and
33
34 Interleukin 8. *J. Infect. Dis.* **2012**, *205*, 1121-1130.
35
36
37 (49) Yu, Y.; Huang, X.; Liu, J.; Zhang, J.; Hu, Y.; Yang, Y.; Huang, Y.; Qin, Q. Fish
38
39 TRIM32 Functions as a Critical Antiviral Molecule Against Iridovirus and
40
41 Nodavirus. *Fish Shellfish Immun.* **2017**, *60*, 33-43.
42
43
44 (50) Schoggins, J.W.; Rice, C.M. Interferon-Stimulated Genes and their Antiviral
45
46 Effector Functions. *Curr. Opin. Virol.* **2011**, *1*, 519-525.
47
48
49 (51) Imaizumi, T.; Yoshida, H.; Hayakari, R.; Xing, F.; Wang, L.; Matsumiya, T.; Tanji,
50
51 K.; Kawaguchi, S.; Murakami, M.; Tanaka, H. Interferon-Stimulated Gene (ISG)
52
53 60, as well as ISG56 and ISG54, Positively Regulates TLR3/IFN-beta/STAT1
54
55
56
57
58
59
60

- 1
2
3 Axis in U373MG Human Astrocytoma Cells. *Neurosci. Res.* **2016**, *105*, 35-41.
4
5
6 (52) Reich, N.C. A Death-Promoting Role for ISG54/IFIT2. *J. Interferon Cytokine*
7
8 *Res.* **2013**, *33*, 199-205.
9
10
11 (53) Von Itzstein, M. The War Against Influenza: Discovery and Development of
12
13 Sialidase Inhibitors. *Nat. Rev. Drug Discov.* **2007**, *6*, 967-974.
14
15
16 (54) Tayyari, F.; Marchant, D.; Moraes, T.J.; Duan, W.; Mastrangelo, P.; Hegele, R.G.
17
18 Identification of Nucleolin as a Cellular Receptor for Human Respiratory
19
20 Syncytial Virus. *Nat. Med.* **2011**, *17*, 1132-1135.
21
22
23 (55) Galdiero, S.; Falanga, A.; Vitiello, M.; Cantisani, M.; Marra, V.; Galdiero, M.
24
25 Silver Nanoparticles as Potential Antiviral Agents. *Molecules* **2011**, *16*,
26
27 8894-8918.
28
29
30 (56) Li, C.M.; Zheng, L.L.; Yang, X.X.; Wan, X.Y.; Wu, W.B.; Zhen, S.J.; Li, Y.F.;
31
32 Luo, L.F.; Huang, C.Z. DNA-AuNP Networks on Cell Membranes as a
33
34 Protective Barrier to Inhibit Viral Attachment, Entry and Budding. *Biomaterials*
35
36 **2016**, *77*, 216-226.
37
38
39 (57) Baram-Pinto, D.; Shukla, S.; Gedanken, A.; Sarid, R. Inhibition of HSV-1
40
41 Attachment, Entry, and Cell-to-Cell Spread by Functionalized Multivalent Gold
42
43 Nanoparticles. *Small* **2010**, *6*, 1044-1050.
44
45
46 (58) Khandelwal, N.; Kaur, G.; Kumar, N.; Tiwari, A. Application of Silver
47
48 Nanoparticles in Viral Inhibition: A New Hope for Antivirals. *Dig. J. Nanomater.*
49
50 *Bios.* **2014**, *9*, 175-186.
51
52
53 (59) Dostalova, S.; Moulick, A.; Milosavljevic, V.; Guran, R.; Kominkova, M.;
54
55
56
57
58
59
60

- 1
2
3 Cihalova, K.; Heger, Z.; Blazkova, L.; Kopel, P.; Hynek, D.; Vaculovicova, M.;
4
5 Adam, V.; Kizek, R. Antiviral Activity of Fullerene C60 Nanocrystals Modified
6
7 with Derivatives of Anionic Antimicrobial Peptide Maximin H5. *Monatsh. Chem.*
8
9
10 **2016**, *147*, 905-918.
- 11
12
13 (60) De Souza, E.S.J.M.; Hanchuk, T.D.; Santos, M.I.; Kobarg, J.; Bajgelman, M.C.;
14
15 Cardoso, M.B. Viral Inhibition Mechanism Mediated by Surface-Modified Silica
16
17 Nanoparticles. *ACS Appl. Mater. Interfaces* **2016**, *8*, 16564-16572.
- 18
19
20 (61) Lisov, A.; Vrublevskaia, V.; Lisova, Z.; Leontievsky, A.; Morenkov, O. A
21
22 2,5-Dihydroxybenzoic Acid-Gelatin Conjugate: The Synthesis, Antiviral Activity
23
24 and Mechanism of Antiviral Action Against Two Alphaherpesviruses. *Viruses*
25
26
27 **2015**, *7*, 5343-5360.
- 28
29
30 (62) Tarr, A.W.; Lafaye, P.; Meredith, L.; Damier-Piolle, L.; Urbanowicz, R.A.; Meola,
31
32 A.; Jestin, J.L.; Brown, R.J.; McKeating, J.A.; Rey, F.A.; Ball, J.K.; Krey, T. An
33
34 Alpaca Nanobody Inhibits Hepatitis C Virus Entry and Cell-to-Cell Transmission.
35
36
37 *Hepatology* **2013**, *58*, 932-939.
- 38
39
40 (63) Sun, R.W.Y.; Chen, R.; Chung, N.P.Y.; Ho, C.M.; Lin, C.L.S.; Che, C.M. Silver
41
42 Nanoparticles Fabricated in HEPES Buffer Exhibit Cytoprotective Activities
43
44 toward HIV-1 Infected Cells. *Chem. Commun.* **2005**, *40*, 5059-5061.
- 45
46
47 (64) Orłowski, P.; Tomaszewska, E.; Gniadek, M.; Baska, P.; Nowakowska, J.;
48
49 Sokolowska, J.; Nowak, Z.; Donten, M.; Celichowski, G.; Grobelny, J.;
50
51 Krzyzowska, M. Tannic Acid Modified Silver Nanoparticles Show Antiviral
52
53 Activity in Herpes Simplex Virus Type 2 Infection. *PloS one* **2014**, *9*, e104113.
54
55
56
57
58
59
60

- 1
2
3
4 (65) Lee, E.C.; Davis-Poynter, N.; Nguyen, C.T.; Peters, A.A.; Monteith, G.R.;
5
6 Strounina, E.; Popat, A.; Ross, B.P. GAG Mimetic Functionalised Solid and
7
8 Mesoporous Silica nanoparticles as Viral Entry Inhibitors of Herpes Simplex
9
10 Type 1 and Type 2 Viruses. *Nanoscale* **2016**, *8*, 16192-16196.
11
12
13 (66) Yang, X.X.; Li, C.M.; Li, Y.F.; Wang, J.; Huang, C.Z. Synergistic Antiviral Effect
14
15 of Curcumin Functionalized Graphene Oxide against Respiratory Syncytial Virus
16
17 Infection. *Nanoscale* **2017**, *9*, 16086-16092.
18
19
20 (67) Li, Y.; Lin, Z.; Zhao, M.; Xu, T.; Wang, C.; Hua, L.; Wang, H.; Xia, H.; Zhu, B.
21
22 Silver Nanoparticle Based Codelivery of Oseltamivir to Inhibit the Activity of
23
24 the H1N1 Influenza Virus through ROS-Mediated Signaling Pathways. *ACS Appl.*
25
26 *Mater. Interfaces* **2016**, *8*, 24385-24393.
27
28
29 (68) Du, T.; Liang, J.; Dong, N.; Liu, L.; Fang, L.; Xiao, S.; Han, H. Carbon Dots as
30
31 Inhibitors of Virus by Activation of Type I Interferon Response. *Carbon* **2016**,
32
33 *110*, 278-285.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract Graphic

